Summary
Stryker Corporation (SYK) reported solid growth in its third quarter and the first nine months of 2006, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. Net sales increased by 10% for the nine-month period and 10% for the third quarter year-over-year, with international sales showing robust growth on a constant currency basis. The company maintained its optimistic outlook for the full year 2006 and projected continued earnings per share growth for 2007, despite some pricing pressures in key markets.
Key Highlights
- 1Stryker reported a 10% increase in net sales for both the first nine months and the third quarter of 2006 compared to the prior year.
- 2The Orthopaedic Implants segment showed an 8% (9% constant currency) increase in sales for the nine months and a 10% (9% constant currency) increase for the third quarter.
- 3The MedSurg Equipment segment demonstrated strong growth, with sales up 15% (15% constant currency) for the nine months and 14% (13% constant currency) for the third quarter.
- 4Domestic sales grew by 11% in both periods, while international sales increased by 7% (9% constant currency) for the nine months and 8% (7% constant currency) for the third quarter.
- 5The company projected full-year 2006 diluted net earnings per share to be $1.89, a 20.4% increase over 2005.
- 6Research, development, and engineering expenses increased by 16% for the nine months, reflecting a continued focus on new product development.
- 7The company maintained a strong liquidity position with $182.7 million in cash and $902.7 million in marketable securities as of September 30, 2006.
Frequently Asked Questions
Stryker's sales growth is primarily driven by increased unit volume and a favorable product mix across its Orthopaedic Implants and MedSurg Equipment segments. Specific product lines like knee implant systems (e.g., Triathlon knee system), trauma implant systems (e.g., Gamma 3 Hip Fracture System), spinal implant systems, and various MedSurg equipment (surgical navigation, imaging systems, patient handling) are showing strong performance.
Stryker adopted FASB Statement No. 123 (revised) regarding share-based payments, recognizing stock option costs. This adoption reduced reported operating and net earnings for the first nine months and third quarter of 2006 and 2005, but the company provides 'adjusted' earnings figures to offer a clearer view of operational performance. Additionally, the company is preparing to adopt FASB Interpretation No. 48 and Statement No. 158 in 2007 and 2006, respectively, which will affect income tax accounting and pension plan disclosures.
Stryker remains optimistic about its outlook for 2006 and 2007. For 2006, it projects diluted net earnings per share of $1.89, a 20.4% increase over 2005. The company also projects diluted net earnings per share of approximately $2.42 for 2007, driven by expected continuing strength in its product lines, despite potential pricing pressures in certain markets.
Stryker is cooperating with ongoing investigations by the Department of Justice related to billing and coding practices of its subsidiary Physiotherapy Associates, and concerning consulting contracts and antitrust matters related to orthopaedic implant devices. The company is also awaiting potential FDA approval for additional OP-1 applications and new product introductions.